Skip to main content
Premium Trial:

Request an Annual Quote

Metamark, Definiens Partner on Cancer Dx

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Metamark Genetics and Definiens today announced that they are collaborating on the development and commercialization of a multiplex platform that will run prognostic and predictive assays for early-stage cancers.

The collaboration will combine Metamark's multiplex protein detection platform with image analysis technology that the Cambridge, Mass.-based firm will jointly develop with Munich, Germany-based Definiens. The firms said that Metamark's quantitative diagnostic approach can "identify and account for small regions of molecularly aggressive cancer cells within an otherwise indolent tumor."

Financial and other terms of the alliance were not disclosed.

"The capability to provide detailed readouts from tissue analysis is opening up new gateways for developing diagnostic assays as we enter the age of personalized medicine," Thomas Colarusso, VP of sales and operations for Definiens, said in a statement. "We believe the Definiens Developer XD and Tissue Studio software will enable Metamark to classify tumor heterogeneity of multiplexed tissue stains and derive prognostic and predictive assays."

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.